Sanofi (SNY)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
- Ticker
- SNY
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- 52-week range
- $39.07 - $52.68
Valuation
- Share price
- $47.04 (close of Nov 6, 2026)
- P/E (TTM)
- 13.09x
- Price to book
- 1.42x
- Price to free cash flow
- 14.17x
Price performance
| Period | Change |
|---|---|
| 1 day | +0.28% |
| 5 days | +6.09% |
| 1 month | +18.91% |
| 3 months | +9.68% |
| 6 months | +7.47% |
| Year to date | -2.93% |
| 1 year | -4.95% |
| 3 years | +3.98% |
| 5 years | -8.29% |
| 10 years | +17.78% |
| All time | +58.01% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 0.54%
- Shares short
- 11.61M
- Days to cover
- 3.09
- Change since prior report
- +9.42%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- 10.90%
- Return on invested capital
- 5.76%
- Return on assets
- 6.16%
- Return on capital employed
- 6.44%
- Gross margin
- 77.17%
- Net margin
- 17.91%
- EBITDA margin
- 14.54%
- Revenue growth
- 6.20%
- Net income growth
- 40.52%
- Free cash flow growth
- 22.53%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 7.06%
- Current ratio
- 1.09x
- Net debt to EBITDA
- 1.02x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Shares outstanding
- 2.44B
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 77.17% | 17.91% | 10.90% | 5.76% |
| 2024-12-31 | 75.66% | 13.53% | 7.14% | 6.32% |
| 2023-12-31 | 76.66% | 14.28% | 7.26% | 6.41% |
| 2022-12-31 | 76.17% | 22.23% | 11.14% | 8.56% |
| 2021-12-31 | 71.29% | 16.48% | 9.01% | 7.44% |
| 2020-12-31 | 69.95% | 34.11% | 19.44% | 14.62% |
| 2019-12-31 | 71.01% | 7.62% | 4.65% | 3.63% |
| 2018-12-31 | 70.34% | 12.49% | 7.29% | 5.18% |
| 2017-12-31 | 70.16% | 24.00% | 14.45% | 5.63% |
| 2016-12-31 | 70.97% | 13.93% | 8.16% | 6.98% |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-30 | Sep 2026 | - |
| 2026-07-30 | Jun 2026 | - |
| 2026-04-23 | Mar 2026 | - |
| 2026-01-29 | Dec 2025 | - |
| 2025-10-24 | Sep 2025 | - |
| 2025-07-31 | Jun 2025 | - |
| 2025-04-24 | Mar 2025 | - |
| 2025-01-30 | Dec 2024 | - |
Filings and sources
- Company website
- sanofi.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades